Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b

Tomokazu Kawaoka, C. Nelson Hayes, Waka Ohishi, Hidenori Ochi, Toshiro Maekawa, Hiromi Abe, Masataka Tsuge, Fukiko Mitsui, Nobuhiko Hiraga, Michio Imamura, Shoichi Takahashi, Michiaki Kubo, Tatsuhiko Tsunoda, Yusuke Nakamura, Hiromitsu Kumada, Kazuaki Chayama

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Background & Aims: Common IL28B locus polymorphisms (SNPs rs8099917 and rs12979860) have been reported to affect peg-interferon plus ribavirin combination therapy (PEG-RBV) for hepatitis C virus (HCV) genotype 1b, but few reports have examined their effect on other two common genotypes, 2a and 2b. Methods: We analyzed predictive factors for sustained virological response (SVR) in a retrospective study of 719 patients with either genotype 2a (530) or 2b (189). Of these patients, 160 were treated with PEG-RBV and 559 were treated with interferon monotherapy. We evaluated predictive factors including HCV RNA, histological findings, IL28B SNP genotypes (rs8099917, rs12979860, and rs12980275), and the effect of treatment regimen and prior treatment history. Results: HCV RNA viral load, treatment regimen, and rs8099917 genotypes independently contributed to the effect of the therapy. For patients treated with PEG-RBV, rs8099917 and viral load were independent predictive factors for SVR in genotype 2b but not in genotype 2a. Conversely, in patients treated with interferon monotherapy, viral load and rs8099917 were independent predictive factors for SVR in genotype 2a but not in genotype 2b. The favorable rs8099917 genotype is also associated with a steep decline in viral load by the second week of treatment. Conclusions: Initial viral load and rs8099917 genotype are significant independent predictors of SVR in genotype 2 patients.

Original languageEnglish
Pages (from-to)408-414
Number of pages7
JournalJournal of Hepatology
Volume54
Issue number3
DOIs
Publication statusPublished - 01-03-2011

Fingerprint

Chronic Hepatitis C
Interferons
Genotype
Viral Load
Therapeutics
Hepacivirus
Single Nucleotide Polymorphism
RNA
Ribavirin
Retrospective Studies
History

All Science Journal Classification (ASJC) codes

  • Hepatology

Cite this

Kawaoka, Tomokazu ; Hayes, C. Nelson ; Ohishi, Waka ; Ochi, Hidenori ; Maekawa, Toshiro ; Abe, Hiromi ; Tsuge, Masataka ; Mitsui, Fukiko ; Hiraga, Nobuhiko ; Imamura, Michio ; Takahashi, Shoichi ; Kubo, Michiaki ; Tsunoda, Tatsuhiko ; Nakamura, Yusuke ; Kumada, Hiromitsu ; Chayama, Kazuaki. / Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b. In: Journal of Hepatology. 2011 ; Vol. 54, No. 3. pp. 408-414.
@article{67b87cf1a6114aff8b847f1d47150d53,
title = "Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b",
abstract = "Background & Aims: Common IL28B locus polymorphisms (SNPs rs8099917 and rs12979860) have been reported to affect peg-interferon plus ribavirin combination therapy (PEG-RBV) for hepatitis C virus (HCV) genotype 1b, but few reports have examined their effect on other two common genotypes, 2a and 2b. Methods: We analyzed predictive factors for sustained virological response (SVR) in a retrospective study of 719 patients with either genotype 2a (530) or 2b (189). Of these patients, 160 were treated with PEG-RBV and 559 were treated with interferon monotherapy. We evaluated predictive factors including HCV RNA, histological findings, IL28B SNP genotypes (rs8099917, rs12979860, and rs12980275), and the effect of treatment regimen and prior treatment history. Results: HCV RNA viral load, treatment regimen, and rs8099917 genotypes independently contributed to the effect of the therapy. For patients treated with PEG-RBV, rs8099917 and viral load were independent predictive factors for SVR in genotype 2b but not in genotype 2a. Conversely, in patients treated with interferon monotherapy, viral load and rs8099917 were independent predictive factors for SVR in genotype 2a but not in genotype 2b. The favorable rs8099917 genotype is also associated with a steep decline in viral load by the second week of treatment. Conclusions: Initial viral load and rs8099917 genotype are significant independent predictors of SVR in genotype 2 patients.",
author = "Tomokazu Kawaoka and Hayes, {C. Nelson} and Waka Ohishi and Hidenori Ochi and Toshiro Maekawa and Hiromi Abe and Masataka Tsuge and Fukiko Mitsui and Nobuhiko Hiraga and Michio Imamura and Shoichi Takahashi and Michiaki Kubo and Tatsuhiko Tsunoda and Yusuke Nakamura and Hiromitsu Kumada and Kazuaki Chayama",
year = "2011",
month = "3",
day = "1",
doi = "10.1016/j.jhep.2010.07.032",
language = "English",
volume = "54",
pages = "408--414",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier",
number = "3",

}

Kawaoka, T, Hayes, CN, Ohishi, W, Ochi, H, Maekawa, T, Abe, H, Tsuge, M, Mitsui, F, Hiraga, N, Imamura, M, Takahashi, S, Kubo, M, Tsunoda, T, Nakamura, Y, Kumada, H & Chayama, K 2011, 'Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b', Journal of Hepatology, vol. 54, no. 3, pp. 408-414. https://doi.org/10.1016/j.jhep.2010.07.032

Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b. / Kawaoka, Tomokazu; Hayes, C. Nelson; Ohishi, Waka; Ochi, Hidenori; Maekawa, Toshiro; Abe, Hiromi; Tsuge, Masataka; Mitsui, Fukiko; Hiraga, Nobuhiko; Imamura, Michio; Takahashi, Shoichi; Kubo, Michiaki; Tsunoda, Tatsuhiko; Nakamura, Yusuke; Kumada, Hiromitsu; Chayama, Kazuaki.

In: Journal of Hepatology, Vol. 54, No. 3, 01.03.2011, p. 408-414.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b

AU - Kawaoka, Tomokazu

AU - Hayes, C. Nelson

AU - Ohishi, Waka

AU - Ochi, Hidenori

AU - Maekawa, Toshiro

AU - Abe, Hiromi

AU - Tsuge, Masataka

AU - Mitsui, Fukiko

AU - Hiraga, Nobuhiko

AU - Imamura, Michio

AU - Takahashi, Shoichi

AU - Kubo, Michiaki

AU - Tsunoda, Tatsuhiko

AU - Nakamura, Yusuke

AU - Kumada, Hiromitsu

AU - Chayama, Kazuaki

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Background & Aims: Common IL28B locus polymorphisms (SNPs rs8099917 and rs12979860) have been reported to affect peg-interferon plus ribavirin combination therapy (PEG-RBV) for hepatitis C virus (HCV) genotype 1b, but few reports have examined their effect on other two common genotypes, 2a and 2b. Methods: We analyzed predictive factors for sustained virological response (SVR) in a retrospective study of 719 patients with either genotype 2a (530) or 2b (189). Of these patients, 160 were treated with PEG-RBV and 559 were treated with interferon monotherapy. We evaluated predictive factors including HCV RNA, histological findings, IL28B SNP genotypes (rs8099917, rs12979860, and rs12980275), and the effect of treatment regimen and prior treatment history. Results: HCV RNA viral load, treatment regimen, and rs8099917 genotypes independently contributed to the effect of the therapy. For patients treated with PEG-RBV, rs8099917 and viral load were independent predictive factors for SVR in genotype 2b but not in genotype 2a. Conversely, in patients treated with interferon monotherapy, viral load and rs8099917 were independent predictive factors for SVR in genotype 2a but not in genotype 2b. The favorable rs8099917 genotype is also associated with a steep decline in viral load by the second week of treatment. Conclusions: Initial viral load and rs8099917 genotype are significant independent predictors of SVR in genotype 2 patients.

AB - Background & Aims: Common IL28B locus polymorphisms (SNPs rs8099917 and rs12979860) have been reported to affect peg-interferon plus ribavirin combination therapy (PEG-RBV) for hepatitis C virus (HCV) genotype 1b, but few reports have examined their effect on other two common genotypes, 2a and 2b. Methods: We analyzed predictive factors for sustained virological response (SVR) in a retrospective study of 719 patients with either genotype 2a (530) or 2b (189). Of these patients, 160 were treated with PEG-RBV and 559 were treated with interferon monotherapy. We evaluated predictive factors including HCV RNA, histological findings, IL28B SNP genotypes (rs8099917, rs12979860, and rs12980275), and the effect of treatment regimen and prior treatment history. Results: HCV RNA viral load, treatment regimen, and rs8099917 genotypes independently contributed to the effect of the therapy. For patients treated with PEG-RBV, rs8099917 and viral load were independent predictive factors for SVR in genotype 2b but not in genotype 2a. Conversely, in patients treated with interferon monotherapy, viral load and rs8099917 were independent predictive factors for SVR in genotype 2a but not in genotype 2b. The favorable rs8099917 genotype is also associated with a steep decline in viral load by the second week of treatment. Conclusions: Initial viral load and rs8099917 genotype are significant independent predictors of SVR in genotype 2 patients.

UR - http://www.scopus.com/inward/record.url?scp=79951675730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951675730&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2010.07.032

DO - 10.1016/j.jhep.2010.07.032

M3 - Article

C2 - 21112660

AN - SCOPUS:79951675730

VL - 54

SP - 408

EP - 414

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 3

ER -